Effect of Tianeptine on Glucose Tolerance with Insulin Secretion in Human: Potential Anti-Diabetic Effect of the Drug

Fuad Lechin*,1, Bertha van der Dijs1, Betty Pardey Maldonado1, Scarlet Baez1 and Marcel E. Lechin2

1Department of Physiological Sciences, Sections of Neuroendocrinology, Neuropharmacology, and Neurochemistry, Instituto de Medicina Experimental, Faculty of Medicine, Universidad Central de Venezuela, Caracas, Venezuela
2Department of Internal Medicine, Texas A & M Health Science Center, College of Medicine, Texas, USA

Abstract: Due to the fact that drugs which interfere with the serotonin (5-HT) uptake (doxepin, sertraline, fluvoxamine and fluoxetine), were able to minimize the insulin release from islet beta-cells and counteract hypoglycemia, we investigated the effects of tianeptine, a drug which enhances 5-HT uptake during the oral glucose tolerance test. We found that the drug triggered significant and sustained insulin rises which were opposite to the plasma glucose decreases. The fact that significant noradrenaline/adrenaline (NA/Ad) plasma ratio paralleled insulin rises throughout the test is consistent with the excitatory role played by the peripheral neural sympathetic activity. Additionally, the positive correlations registered between NA versus DA (dopamine) plasma levels indicate that the latter arose from sympathetic nerves rather than the adrenal glands. Furthermore, the significant reductions of both platelet and plasma 5-HT registered throughout the OGTT plus tianeptine test support the postulation that reduction of the parasympathetic drives is occurring. This parasympathetic drive is responsible for the secretion of 5-HT from the enterochromaffin cells. Finally, considering that circulating 5-HT excites alpha-cells and modulates beta-cells, it is possible to infer that minimization of this factor contributed to the insulinoenic effect displayed by the association of this drug to an oral glucose load. We also discussed the peripheral and central nervous system mechanisms responsible for the insulinoenic effect registered throughout the test.

Keywords: Diabetes, hyperinsulinism, neural sympathetic activity, serotonin, tianeptine.

INTRODUCTION

The concept of "entero-insular axis" began in 1962 when we demonstrated that the gastrointestinal (GI) hormone secretin was found to be able to excite the release of not only the pancreatic exocrine secretion but also the endocrine (insular) activity [1-3]. It was demonstrated that this gastrointestinal factor acted at the beta-cell level. In addition, it was also found that another gastrointestinal factor, serotonin (5-HT), was able to inhibit the insulin release in vitro [4,5]. The above findings were further ratified by multiple research studies [6,7]. Furthermore, whereas intraportal infusion of serotonin was able to inhibit the stimulated insulin secretion in dogs [5], insulin (subcutaneously injected) was able to elevate platelet serotonin (p5-HT) circulating levels in essential hypertensive patients but not in non-essential hypertensive or normal subjects [7]. This phenomenon was attributed to the hyperactivity of neural sympathetic system plus the hypoactivity of the adrenal glands secretion always observed in the essential hypertensive subjects. Moreover, many studies carried out by other researchers ratified our preliminary findings and even showed that not only serotonin but other GI factors were also able to control the secretion of insulin by beta cells [8]. The above information has been quoted in our review article discussing hyperinsulinism [9].

Other research studies carried out in our department demonstrated that the experimentally-induced depression (captivity) was able to provoke a diabetogenic effect in dogs [10]. The fact that these dogs showed greatly increased p5-HT, and that in addition normalization of the OGTT plus p5-HT levels paralleled both the disappearance of the psychological disorder as well as the diabetic syndrome; led us to postulate that serotonin played a primary role in the inhibition of the islet beta-cells [11,12]. Furthermore, we also demonstrated that the chronic administration of some dopaminergic (DA) blocking agents like sulpiride, were able to provoke a diabetogenic effect plus a p5-HT elevation similar to that registered during captivity [11]. Evenmore, the fact that normalization of clinical, hormonal and glucose parameters was observed after the interruption of drug administration allowed us to postulate that serotonin was the common etiopathogenic factor responsible for both the metabolic and the psychiatric disorder [13]. The above findings were furtherly confirmed and published [9,14,15]. Finally, our demonstration dealing with the annulment by doxepin (a serotonin uptake inhibitor) of the hyperinsulinism plus hypoglycemia syndrome, affecting a great bulk of patients [16] led us to assess the possible insulinoenic effect of drugs like tianeptine which enhances rather than inhibits the uptake of 5-HT [17].

MATERIALS AND METHODOLOGY

One OGTT plus placebo and one OGTT plus tianeptine test were carried out 2 weeks apart in 48 caucasic normal voluntary humans (26 males and 22 females), whose ages
ranged from 20 to 63 years (Mean ± s.e.m. = 42.6 ± 5.8). All of them gave informed written consent and the procedure was approved by the ethical committee of FUNDAIME. All subjects were within 10% of ideal body weight, and none had undergone abdominal surgery or were taking any medications. None of the subjects had physical or psychiatric illness. Subjects were rated on a modified Hamilton Depression Rating Scale for Depression and all of them completed the self-rating Beck Depression Inventory [16] in order to discard subjects with depression. Pregnancy, lactation, smoking and/or alcoholism also excluded subjects.

Analytical Methods

Noradrenaline (NA), adrenaline (Ad), dopamine (DA), plasma free serotonin (f5-HT), platelet serotonin (p5-HT), glucose and insulin were measured throughout the 180 minute testing period. For all parameters, the samples were assayed in duplicate and all determinations were made simultaneously. We used reverse-phase, ion-pair high performance liquid chromatography with electrochemical detection for the detection of monoamines. Optimization of chromatographic conditions and attainment of adequate quantification parameters allowed us to maximize sensitivity and reproducibility.

All tests were performed on recumbent subjects, after 14 hours of fasting. A heparinized venous catheter was inserted into a forearm vein at least 30 min before beginning the tests. Blood samples were collected at 0, 60, 90, 120 and 180 minutes. Each subject drank a 30% glucose solution (1 g/kg of ideal body weight) plus placebo or an oral dose of tianeptine (12.5 mg = one tablet). Blood for catecholamines and serotonin assays was transferred to plastic tubes, each containing 20 mg of EDTA plus 10 mg of sodium bisulfite/ml of solution. The tubes were carefully inverted and placed on ice. The blood was promptly centrifuged at 600 rpm for 15 min at 4°C in order to obtain platelet-rich plasma. Two milliliters of platelet-rich plasma, obtained for determination of platelet serotonin (p5-HT), were taken and stored at −70 °C until assayed. The remaining blood was again centrifuged at 7,000 rpm. The supernatant, platelet-poor plasma, was divided into two portions for determination of catecholamines and f5-HT, after which both portions were stored at −70 °C until assayed.

A physician in constant attendance noted any symptoms reported by the subjects and monitored heart rate, systolic blood pressure and diastolic blood pressure every 30 minutes.

Reagents and Standards

Noradrenaline, adrenaline, dopamine, serotonin creatinine sulphate, dihydroxybenzylamine, sodium octyl sulphate, dibutylamine, acid-washed aluminium oxide, Na2HPO4, citric acid and EDTA were purchased from Sigma-Aldrich (St Louis, MO, USA). Microfilters were purchased from Whatman Inc. (Florham Park, NY, USA) both platelet-rich and platelet-poor plasma were processed in the same manner as the samples. The mobile phase was KH2PO4 6.8045 g/L, EDTA 0.100 gm/L and di-N-butylamine 100 μL/L. Sodium octyl sulphate was added as ion-pair agent in a concentration of 0.6125 g/L with a pH adjusted to 5.6. The sensitivity of this method for NA, Ad and DA (50, 25 and 25 ng/ml, respectively) were added to the plasma pool. Both the standard plasma and the sample plasma were supplemented with 20 μl of internal standard (100 ng/ml of dihydroxybenzylamine). The mobile phase was KH2PO4 6.8045 g/L, EDTA 0.100 gm/L and di-N-butylamine 100 μL/L. Sodium octyl sulphate was added as ion-pair agent in a concentration of 0.6125 g/L with the pH adjusted to 5.6. The sensitivity of the method for NA, Ad and DA was 6.4, 5.8 and 2.0 pg/ml, respectively. The intra-assay coefficients of variation were 2.8, 4.0 and 4.0 %, respectively. The inter-assay coefficients of variation were 6.7, 4.5 and 4.3 %, respectively.

Plasma indoleamines. After sonication of platelet-rich plasma to disrupt the platelets (Ultrasonic Liquid Processor, model 385; Heat Systems Ultrasonics Inc., Farmingdale, NY, USA), both platelet-rich and platelet-poor plasma were processed in the same way: 200μl of 3.4 mol/L perchloric acid and 50 μl of 5-hydroxy-tryptophan solution (114.5 μg/ml) as internal standard, were added to 1 ml of plasma vortexed and centrifuged at 10,000 rpm for 15 min at 4°C. The supernatant was filtered through a 0.22 μm membrane (Millipore) and 10 μl was injected into the column. Calibration runs were generated by spiking blank platelet-poor plasma with 50 μl of a solution containing 5-HT (10 μg/ml) and 50 μl of 5-hydroxy-tryptophan (114.5 μg/ml). This standard plasma was processed in the same manner as the samples. The mobile phase was citric acid 3.8424 g/L, sodium acetate 4.1015 g/L, EDTA 0.100 g/L, di-N-butylamine 100 μL/L and 30 ml/L of 2-propanol. Sodium octyl sulphate was added as ion-pair agent in a concentration of 4.25 mg/L with a pH of 5.0. The sensitivity of the method
The assessment of circulating neurotransmitters after an oral glucose load carried out according to the present protocol ratified other previously published research studies [18]. Only NA and p5-HT circulating values showed significant and sustained rises that paralleled insulin increases and opposed plasma glucose reductions. In addition, Ad and DA showed significant decreases at the 90min, 120, and 180min periods. All subjects fell asleep and displayed rapid eye movements (REM) during the test. Maximal rise of glucose was registered at the 30min period, whereas minimal mean values were reached at the 180min period. In addition to the above, although both NA and p5-HT levels were raised after the oral glucose load, the NA/p5-HT ratio showed significant decreases throughout the OGTT.

All subjects showed a normal OGTT. Normal rises of glucose and insulin were registered throughout the test (Fig. 1). Aside from glucose rise, significant increases in NA (Fig. 2), NA/Ad (Fig. 3), and p5-HT (Fig. 4) were registered. Significant reduction of Ad values were registered throughout the test. No significant changes were observed in DA and f5-HT. Slight but significant decreases of heart rate and systolic blood pressure (SBP) mean ± s.e.m. values were registered throughout the test. Significant reductions in the NA/p5-HT (Fig. 3), Ad/p5-HT and DA/p5-HT ratios mean values were also registered at 60, 90, 120 and 180min (Fig. 5). All of our subjects fell asleep and displayed REM during
OGTT, especially accentuated at these same periods (90 and 180min). Correlations are in Table 1.

**Oral Glucose + Tianeptine Test**

Subjects did not show drowsiness throughout the test. This fact, in contraposition with the other one occurred in the glucose challenge alone, may be associated with the decreased circulating levels of serotonin observed with the addition of tianeptine. The potentiation of insulin secretion triggered by a small dose of oral tianeptine when added to an oral glucose dose (Fig. 1), should be associated with the changes of the autonomic nervous system parameters registered in this study, namely, the increase of both NA and DA plus the decreases of Ad (Fig. 2), p5-HT and f5-HT circulating levels (Fig. 4). With respect to this, we will discuss the possible physiological and pharmacological mechanisms underlying the above findings.

**Plasma Catecholamine Changes**

The close positive correlations registered between NA and NA/Ad ratio when these parameters were plotted versus DA strongly suggest that the latter arose from the sympathetic nerves rather than the adrenal glands (Table 2). Furthermore, the significant positive correlations registered between NA and DA versus diastolic blood pressure (DBP), but not versus SBP and heart rate (Table 3), indicates that neural not adrenal sympathetic activity was responsible for these changes.

**Circulating Indolamine Changes**

The significant reductions of both p5-HT and f5-HT indicate that the normal post-glucose enhancement of these indoleamines was reversed by the drug (Fig. 4). No significant correlations were found between these parameters when plotted against catecholamines before or after the administration of the glucose load.

**Plasma Glucose Changes**

Small but significant rise of glucose levels were registered at the 30min and 60min post-glucose periods. Non significant increases were found at the 90min, 120min and 180min post-glucose periods (Fig. 1).
Fig. (3). The addition of tianeptine to an oral glucose load reversed the plasma serotonin (f5-HT) and platelet serotonin (p5-HT) rises, normally registered throughout this test without the drug. (n = 48) Values are expressed as mean ± s.e.m. (**) \( p < 0.02; (***) \( p < 0.01 \) (OGTT + Tianeptine versus OGTT + Placebo).

Fig. (4). The addition of tianeptine to an oral glucose load potentiated the normal NA/Ad ratio registered throughout this test without the drug. It also provoked the enhancement of the NA/p5-HT ratio triggered by both the NA rises and the p5-HT fall. (n = 48) Values are expressed as mean ± s.e.m. (*) \( p < 0.05; (***) \( p < 0.01 \) (OGTT + Tianeptine versus OGTT + Placebo).
Insulinogenic Effect of Tianeptine

The Open Neuroendocrinology Journal, 2009, Volume 2

Significant, progressive and sustained insulin rises were registered starting with the first 30min period until the final 180 min period (Fig. 1).

Correlations

Significant positive correlations were noted between NA versus DA; NA/Ad versus DA; NA/Ad versus DBP; NA versus insulin; NA/Ad versus insulin; and DA versus insulin at the 60min, 90min, 120min and 180 min periods. Significant negative correlations were found between DA versus DBP at the last four periods (Table 2).

DISCUSSION

The potentiation of the insulin secretion triggered by the addition of a small dose of tianeptine to an oral glucose load should be associated with the enhancement of neural sympathetic activity registered in this study as inferred from the close positive and negative correlations we found between NA versus DA and NA versus Ad, respectively, as well as from the significant positive correlations demonstrated between NA versus insulin and DA versus insulin. Conversely, significant negative NA versus p5-HT and DA versus p5-HT correlations were registered during the post-glucose + tianeptine trial. These findings fit well with the progressive and significant reduction of p5-HT and increases of NA and DA values registered throughout the trial. In addition, it may explain the absence of sleep registered in this group. This fact contrasts with other one showing that the oral glucose challenge provokes sleep in normal subjects. This effect is positively correlated with the increase of circulating serotonin, always registered in them [18]. On the other hand, the maximal fall of both Ad and f5-HT values interfered with the statistical assessment dealing with these parameters. These effects should be associated with the well known fact that insulin crosses the blood brain barrier and excites the A5(NA) neurons. These latter are responsible for the peripheral neural sympathetic activity which exerts hypoglycemic effects at peripheral level.

Peripheral Mechanisms

Serotonin released from the enterochromaffin cells (ECC) during postprandial parasympathetic drives [19,20] modulates both beta and alpha cells [21]. It is incorporated
into the insulin granules of the former [22,23], at which level
exerts a modulatory effect [24-27]. Conversely, 5-HT
facilitates the secretion of glucagon from the alpha cells into
the blood stream [21,28-30]. Both serotonin and glucagon
trigger the secretion of Ad from the adrenal glands and they
excite hepatic glucogenolysis which counteract the
hypoglycemic effect of the insulin released from beta cells.
Thus, the overwhelming insulinogenic effect triggered by the
addition of tianeptine to an oral glucose load should annul
the alpha-cell plus adrenal gland cascade.

Findings showed that serotonin loaded into the beta cells
localizes to the insulin secretory granules and is additionally
co-released with it [26,27]. These authors demonstrated that
there is little exocytic activity of insulin + 5-HT at the
basal glucose level, but increasing the sugar concentration
results in increased insulin release from perfused beta cells.
Furthermore, Deeney et al. [26] concluded that serotonin
might be considered as a marker for insulin release. Thus,
this modulatory mechanism would be favored by the drug.

In addition to the above and taking into account that
plasma serotonin excites both alpha-cells and adrenal glands
directly [21,29,31-34], the disappearance of those
hyperglycemic factors would favor the predominance of the
insulinogenic effect registered in this study. This phenomenon should be associated with other findings showing that adrenalectomy is able to interfere with the glucagon induced plasma glucose rises provoked by intravenous administration of 5-HT [35]. Finally, the fact that methysergide, a 5-HT antagonist, can prevent the glucagon effects, affords additional support to the postulation that serotonin was the responsible factor for the above phenomenon by acting at the islet cells directly [28,36].

The above comments are reinforced by others showing that intraperitoneally injected serotonin increases glucagon plus glucose and reduces insulin plasma levels; thus, the annulment of these effects triggered by the addition of tianeptine to the oral glucose load should be attributed to the interference by the drug, not only at CNS, but also at the peripheral level. In addition, the fact that adrenomedullation prevented both the glucose rise and the insulin fall, but not the glucagon rise, indicated that the effects at the beta-cell level were mediated by the adrenaline released from the adrenal glands [21,29,31,33,34,37,38].

The peripheral neural sympathetic over-activity registered during the glucose plus tianeptine trial fits well with the minimization of the parasympathetic drive which excites the ECC system, as inferred by the lowering of p5-HT circulating levels observed throughout the test. This parasympathetic mechanism is bridled by sympathetic

### Table 1. Correlations (r) Found During the Oral Glucose Tolerance + Placebo Test Performed in 48 Normal Voluntary Humans (26 Males and 22 Females)

<table>
<thead>
<tr>
<th>PERIODS</th>
<th>0min</th>
<th>30min</th>
<th>60min</th>
<th>90min</th>
<th>120min</th>
<th>180min</th>
</tr>
</thead>
<tbody>
<tr>
<td>NA vs Ad</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>NA vs DA</td>
<td>n.s.</td>
<td>n.s.</td>
<td>.203*</td>
<td>.256*</td>
<td>.321**</td>
<td>.293**</td>
</tr>
<tr>
<td>Ad vs DA</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>NA vs Glycemia</td>
<td>n.s.</td>
<td>n.s.</td>
<td>-.221*</td>
<td>-.325**</td>
<td>-.442**</td>
<td>-.456**</td>
</tr>
<tr>
<td>DA vs Glycemia</td>
<td>n.s.</td>
<td>n.s.</td>
<td>-.211*</td>
<td>-.247*</td>
<td>-.354**</td>
<td>-.376**</td>
</tr>
<tr>
<td>Ad vs Glycemia</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>NA vs p-5-HT</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>Ad vs p-5-HT</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>DA vs p-5-HT</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>p-5-HT vs Glycemia</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>NA vs Insulin</td>
<td>n.s.</td>
<td>n.s.</td>
<td>.325*</td>
<td>.411**</td>
<td>.401**</td>
<td>.397**</td>
</tr>
<tr>
<td>DA vs Insulin</td>
<td>n.s.</td>
<td>n.s.</td>
<td>.214*</td>
<td>.222*</td>
<td>.216*</td>
<td>.217*</td>
</tr>
<tr>
<td>Ad vs Insulin</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>p-5-HT vs Insulin</td>
<td>n.s.</td>
<td>n.s.</td>
<td>-.212*</td>
<td>-.223</td>
<td>-.231*</td>
<td>-.214*</td>
</tr>
<tr>
<td>NA vs HR</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>Ad vs HR</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>DA vs HR</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>NA/Ad vs SBP</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>NA/Ad vs DBP</td>
<td>n.s.</td>
<td>n.s.</td>
<td>.207*</td>
<td>.214*</td>
<td>.221*</td>
<td>.218*</td>
</tr>
<tr>
<td>DA vs SBP</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>DA vs DBP</td>
<td>n.s.</td>
<td>n.s.</td>
<td>-.213*</td>
<td>-.210*</td>
<td>-.220*</td>
<td>-.222*</td>
</tr>
</tbody>
</table>

Levels of significance: (*) p < 0.02; (**) p < 0.01. n.s. = non significant. NA = noradrenaline; Ad = adrenaline; DA = dopamine; p-5-HT = platelet serotonin; HR = heart rate; SBP = systolic blood pressure; DBP = diastolic blood pressure.
nerves. With respect to this, it should be known that f5-HT but not p5-HT is able to excite the medullary area postrema (AP), which sends modulatory axons to both vagal and adrenergic medullary nuclei, responsible for the parasympathetic and adrenal sympathetic peripheral activities, respectively [20,39-41]. These activities were minimized throughout the OGTT + tianeptine test because of the fall of f5-HT. With respect to this, it should be known that both circulating Ad and ACh are able to increase f5-HT, the former because it triggers platelet aggregation, whereas the latter through the interference with the platelet uptake of serotonin [42].

In short, the annulment of both adrenal sympathetic and parasympathetic activities registered in this study should be associated to the suppression of the stimulatory drives by f5-HT at the area postrema, which sends excitatory and inhibitory axons to the medullary vagal complex and the C1(Ad) nuclei, respectively [43,44]. With respect to the above, it should be known that the C1(Ad) nuclei interchanges inhibitory axons with A5(NA) pontomedullary nucleus, responsible for neural sympathetic activity [45,46] thus, the disappearance of the activity of the former, triggered by tianeptine minimized the peripheral adrenal sympathetic drive and favored the absolute predominance of the neural sympathetic activity registered in the present study. With respect to the latter, exhaustive evidence has demonstrated that insulin crosses the blood brain barrier and excites the A5(NA) nucleus responsible for the activity of sympathetic nerves [9,47-49].
It is well known that at CNS level, tianeptine triggers the absolute disappearance of 5-HT from synaptic clefts. With respect to this, it should be known that the C1(Ad) medullary nuclei responsible for the adrenal glands activity [44] receive excitatory 5-HT axons from the dorsal raphe DR(5-HT) nucleus [50,51] and also from the medullary serotoninergic nuclei: raphe magnus, raphe obscurus and raphe pallidus [52]. Thus, the drug should interfere with these excitatory drives to the C1(Ad) nuclei. In addition, exhaustive evidence has demonstrated that serotonin released at the hypothalamic level is responsible for the neuroendocrine cascade which excites the adrenal glands secretion thus; this excitatory adrenergic drive should also be suppressed by tianeptine [51].

In summary, considering that 5-HT is taken up by serotoninergic axons, platelets and beta cells, tianeptine, a drug which enhances this mechanism, should eliminate this serotoninergic hyperglycemic effect, which interfere with the insulin secretion. This postulation fits well with the ability of drugs that interfere rather than enhance 5-HT uptake (like doxepin, sertraline, paroxetine or fluvoxamine) to counteract hyper-insulinism + hypoglycemia syndrome [16,53].

We should also comment the DA plasma rises registered in this study. These findings are in line with our preliminary research studies showing that the diabetogenic effect triggered by captivity and/or sulpiride was positively and negatively correlated with 5-HT and DA blood levels, respectively [11-13]. This circulating neurotransmitters profile contrasts with the effects reported in this study. Furthermore, the significant NA versus DA positive correlations shown in the present research work indicates that both catecholamines have arisen from the sympathetic nerves. Finally, these findings agree with others showing that DA plays a direct excitatory role at the beta-cells level [54].

At the CNS level, findings showed that both insulin and glucagon crosses the blood brain barrier and excite the A5(NA) [55] and the C1(Ad) [56] pontomedullary nuclei responsible for the neural and adrenal sympathetic activities, respectively, thus, the predominance of the former mechanism registered in the present study is in accordance with the above.

Summarizing, both insulin and glucagon crosses the blood brain barrier and excites the C1(Ad) medullary nuclei and the A5(NA), respectively. Both nuclei interchange inhibitory axons [9,45]. Predominance of the former would result in neural sympathetic activity plus hyperinsulinism + hypoglycemia whereas, the opposite peripheral profile depends on the overactivity of the C1(Ad) nuclei (adrenal sympathetic excitation plus hyperglycemia). This catecholaminergic binomial CNS axis is modulated by the CNS serotoninergic axons arising from the pontine dorsal raphe (DR), median raphe (MR) nuclei and the medullary serotoninergic system which includes the raphe magnus, raphe obscurus and raphe pallidus nuclei. A great bulk of quoted evidence has demonstrated that whereas the DR(5-HT) is positively correlated with adrenal sympathetic activity, the MR(5-HT) potentiates the neural sympathetic branch [52]. The enhancement of neural sympathetic activity + hyperinsulinism registered in the present study strongly suggests that the drug suppressed the activity of the DR(5-HT) + C1(Ad) axis which favored the disinhibition of the A5(NA) plus the MR(5-HT) binomial [57]. Thus, the potentiation by tianeptine of the normal glucose-induced neural sympathetic activity should be added to the minimization of both the parasympathetic plus the adrenal sympathetic activities which redound in the absolute predominance of the neural sympathetic system.

CONCLUSIONS

Type-2 diabetes depends on the unbalance between insulin and glucagon, at peripheral level. However, considering that both hormones cross the blood brain barrier and excite the C1(Ad) and the A5(NA) nuclei, respectively, we postulated that an adequate neuropharmacological manipulation at the CNS level would facilitate the predominance of the latter over the former favoring the hypoglycemic effect of the insulin. In accordance with this hypothesis, we were able to demonstrate that tianeptine, a drug which reduces serotonin levels at both plasma and synaptic clefts, was able to enhance plasma insulin throughout the oral glucose tolerance test in normal subjects. The facts showing that the plasma NA rises and blood serotonin decreases showed significant positive and negative correlations with insulin levels, respectively, allowed us to postulate that tianeptine should be a powerful neuropharmacological drug to treat diabetic patients.

REFERENCES

Insulinogenic Effect of Tianeptine

The Open Neuroendocrinology Journal, 2009, Volume 2

19


[34] Orer HS, Geiber GL, Barman SM. Role of serotoninergic input to the ventrolateral medulla in expression of the 10-Hz sympathetic nerve rhythm. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1435-44.


